Use of an antimicrobial peptide TP4 in treating a cancer

    公开(公告)号:US10232013B2

    公开(公告)日:2019-03-19

    申请号:US15403595

    申请日:2017-01-11

    Abstract: The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia (Oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (TNBC) with TP4.

    Method for high efficiency protein delivery into plastids

    公开(公告)号:US10184128B2

    公开(公告)日:2019-01-22

    申请号:US15210445

    申请日:2016-07-14

    Abstract: The present invention provides a recombinant DNA molecule encoding a fusion protein, comprising a first DNA sequence encoding a high-efficiency transit peptide operably linked to a second DNA sequence encoding a passenger protein, wherein the high-efficiency transit peptide is selected from the group consisting of transit peptides of the precursors of translocon at the inner envelope membrane of chloroplasts 40 kD (prTic40), chaperonin 10-2 (prCpn10-2), Fibrillin 1B (prFibrillin), ATP sulfurylase 1 (prAPS1), ATP sulfurylase 3 (prAPS3), 5′-adenylylsulfate reductase 3 (prAPR3), stromal ascorbate peroxidase (prsAPX), prTic40-E2A (a prTic40 variant), prCpn10-1-ΔC7C37S (a chaperonin 10-1 variant), a functional fragment of any of the transit peptides and an equivalent thereof. And the present invention also provides a method of high efficiency delivery of a protein into plastids using the high-efficiency transit peptides.

    Method for treating influenza A virus infection

    公开(公告)号:US10172919B2

    公开(公告)日:2019-01-08

    申请号:US15537051

    申请日:2015-12-29

    Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.

Patent Agency Ranking